Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 14/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409261 | 0.93 | TEAD1 (0.45) | TEAD1JAK3CCR2TEAD3BTK | |
| SCHEMBL1628867 | 0.87 | JAK3 (0.41) | TEAD1JAK3JAK1BTK | |
| SCHEMBL410336 | 0.87 | JAK3 (0.41) | TEAD1JAK3JAK1BTK | |
| SCHEMBL1628865 | 0.87 | JAK3 (0.41) | TEAD1JAK3JAK1BTK | |
| SCHEMBL1629421 | 0.83 | TEAD1 (0.40) | TEAD1JAK3TEAD3BTK | |
| SCHEMBL1630022 | 0.83 | TEAD1 (0.40) | TEAD1JAK3TEAD3BTK | |
| SCHEMBL14479237 | 0.83 | TEAD1 (0.40) | TEAD1JAK3TEAD3BTK | |
| SCHEMBL20937623 | 0.83 | JAK3 (0.36) | TEAD1JAK3CCR2BTK | |
| SCHEMBL19229727 | 0.82 | JAK3 (0.38) | TEAD1JAK3JAK1BTK | |
| SCHEMBL25366029 | 0.82 | CCR2 (0.42) | JAK3CCR2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | KJ CHEMICALS CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4435021-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | KJ Chemicals Corporation (JP) | 2024-09-25 | — | — | EP | disclosed |
| CN-118251428-A | Active energy ray-curable composition | 科巨希化学股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023090302-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | ＫＪケミカルズ株式会社 | 2023-05-25 | — | — | WO | disclosed |
| EP-3689871-B1 | 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | PARP1, CAP1, XRN2 | TEAD1 2946/4885JAK3 4098/4885CCR2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.